Filip Dubovsky notified Novavax, Inc. (the ?Company?) of his decision to retire as President, Research and Development, effective as of June 30, 2024. Dr. Dubovsky will continue to provide consulting services to the Company following his retirement, as further described below. The post-termination period applicable to Dr. Dubovsky?s current non-competition and non-solicitation covenants will commence upon his retirement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.4 USD | -4.32% |
|
-20.75% | +200.00% |
06-14 | Novavax Files Emergency Use Authorization Amendment For Updated COVID-19 Vaccine | MT |
06-14 | FDA asks COVID vaccine makers to target KP.2 strain with updated shots | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+200.00% | 2.02B | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024